$25.90
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
Key stats
Open
$25.54
Volume
1.00M
Market cap
$23.51B
Prev. close
$26.01
Impl / hst vl
-
Open interest
$0.00
$25.39
Day’s Range
$26.60
$15.96
52W Range
$27.50
Valuation
44
Valuation score
Fairly Valued
P/E
-
P/S
6.67
P/B
4.94
Current ratio
2.13
Debt / Equity
0.39
ROE
-27.43%
Gross margin
60.25%
Income growth
-0.37%
FCF growth
89.66
Analysts estimates
Consensus rating
Buy
The average rating from top 9 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$27.65
The top 10 analysts forecasts that 12-month price may increase by 6.77%, with a low of $19.33 and a high of $37.43
$19.33
Low
$27.65
Avg
$37.43
High
Current price
Earnings
Q2 ‘26 revenue
$106.31M
Q2 ‘26 net income
-$50.83M
Revenue
Net income
Previous EPS
-$0.05
Estimate EPS
-$0.07
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply